Literature DB >> 10091176

High incidence of osteoporosis in thalassaemia major.

C E Jensen1, S M Tuck, J E Agnew, S Koneru, R W Morris, A Yardumian, E Prescott, A V Hoffbrand, B Wonke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10091176

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN： 0334-018X            Impact factor:   1.634


× No keyword cloud information.
  13 in total

1.  Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.

Authors:  Maria G Vogiatzi; Jaime Tsay; Kostas Verdelis; Stefano Rivella; Robert W Grady; Stephen Doty; Patricia J Giardina; Adele L Boskey
Journal:  Calcif Tissue Int       Date:  2010-05-07       Impact factor: 4.333

2.  A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major.

Authors:  M Dimitriadou; A Christoforidis; L Fidani; M Economou; E Vlachaki; M Athanassiou-Metaxa; G Katzos
Journal:  Osteoporos Int       Date:  2015-08-15       Impact factor: 4.507

3.  Prevalence of fractures among the Thalassemia syndromes in North America.

Authors:  M G Vogiatzi; E A Macklin; E B Fung; E Vichinsky; N Olivieri; J Kwiatkowski; A Cohen; E Neufeld; P J Giardina
Journal:  Bone       Date:  2005-11-17       Impact factor: 4.398

4.  Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Grigorios Rombopoulos; Victoria Kaltzidou; Eugenia Katounda; Dimitrios Kaltsas; George Tolis
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Eugenia Katounda; Grigorios Rombopoulos; Victoria Kaltzidou; Dimitrios Kaltsas; Sophia Malaktari; Vassilis Athanasiou; George Tolis
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

6.  Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells.

Authors:  M Doyard; N Fatih; A Monnier; M L Island; M Aubry; P Leroyer; R Bouvet; G Chalès; J Mosser; O Loréal; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2012-01-12       Impact factor: 4.507

7.  Prolidase activity and oxidative status in patients with thalassemia major.

Authors:  Alpay Cakmak; Murat Soker; Ahmet Koc; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 8.  Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

Authors:  A Gaudio; N Morabito; A Xourafa; I Macrì; A Meo; S Morgante; A Trifiletti; A Lasco; N Frisina
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 9.  Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.

Authors:  M Mamtani; H Kulkarni
Journal:  Osteoporos Int       Date:  2009-02-26       Impact factor: 4.507

10.  Bone disease in thalassemia: a frequent and still unresolved problem.

Authors:  Maria G Vogiatzi; Eric A Macklin; Ellen B Fung; Angela M Cheung; Elliot Vichinsky; Nancy Olivieri; Melanie Kirby; Janet L Kwiatkowski; Melody Cunningham; Ingrid A Holm; Joseph Lane; Robert Schneider; Martin Fleisher; Robert W Grady; Charles C Peterson; Patricia J Giardina
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.